Tonix Pharmaceuticals Q2 EPS $(2.68) Beats $(2.78) Estimate
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals reported Q2 losses of $(2.68) per share, beating the analyst consensus estimate of $(2.78) by 3.6 percent. This represents a 64.88 percent increase over losses from the same period last year.
August 10, 2023 | 8:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' Q2 losses were less than expected, indicating a positive trend in the company's financial performance.
Tonix Pharmaceuticals reported lower than expected losses for Q2, which is a positive sign for the company's financial health. This could lead to increased investor confidence and potentially a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100